← Leaderboards
Jorge R Kizer
Weill Medical College Of Cornell Univ
$10,067,369
Attributed
$29,206,854
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,206,854 · 12
By mechanism
R01$25,814,733 · 6
RM1$1,969,877 · 1
K23$653,080 · 1
K24$606,095 · 1
M01$163,069 · 3
Top collaborators
- Joao A C Lima10 shared
- Robert C Kaplan7 shared
- Robert D. Burk6 shared
- Steven R Cummings6 shared
- Peter Ganz6 shared
- Anne B Newman6 shared
- Russell P Tracy6 shared
- Alice A. Arnold4 shared
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortRisk FactorsCardiovascular DiseasesCardiovascular SystemEvaluationPathway InteractionsHeart FailureMyocardialElderlyBlood VesselsFunctional DisorderPrevalenceLinkMyocardial DysfunctionDiabetes MellitusCardiovascular Disorder RiskFollow-UpFibrosisPathogenesisCardiacPhenotypePreventResearch PersonnelPrevention
Grant awards (42)
Stimulant and Polysubstance use, Inflammation and Sex Effects on Myocardial Disease in HIV (SPISE)$1,969,877
RM1 · FY2025 · DA
Multi-omic signatures of gut dysbiosis and cardiovascular comorbidities associated with HIV infection$705,769
R01 · FY2025 · HL
Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults$695,447
R01 · FY2025 · DK
Multi-omic signatures of gut dysbiosis and cardiovascular comorbidities associated with HIV infection$700,116
R01 · FY2024 · HL
Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults$645,272
R01 · FY2024 · DK
Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults$772,730
R01 · FY2023 · DK
Multi-omic signatures of gut dysbiosis and cardiovascular comorbidities associated with HIV infection$757,962
R01 · FY2023 · HL
Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos$2,271,824
R01 · FY2022 · HL · contact PI
Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos$19,326
R01 · FY2022 · HL · contact PI
Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos$2,278,867
R01 · FY2021 · HL · contact PI
Advanced Glycation Endproducts and Cardio-Renal Disease$121,219
K24 · FY2021 · HL · contact PI
Clinical, Molecular, and Genetic Determinants of MRI-determined Left Atrial Phenotypes$19,699
R01 · FY2021 · HL · contact PI
Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos$2,303,826
R01 · FY2020 · HL · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2020 · AG
Advanced Glycation Endproducts and Cardio-Renal Disease$121,219
K24 · FY2020 · HL · contact PI
Non-alcoholic Fatty Liver Disease and Cardiovascular Disease in Hispanics/Latinos$2,425,096
R01 · FY2019 · HL · contact PI
Evaluation of HIV-associated Cardiac Dysfunction in Women$706,647
R01 · FY2019 · HL · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2019 · AG
Advanced Glycation Endproducts and Cardio-Renal Disease$121,219
K24 · FY2019 · HL · contact PI
Evaluation of HIV-associated Cardiac Dysfunction in Women$812,548
R01 · FY2018 · HL · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2018 · AG
Advanced Glycation Endproducts and Cardio-Renal Disease$121,219
K24 · FY2018 · HL · contact PI
Evaluation of HIV-associated Cardiac Dysfunction in Women$817,073
R01 · FY2017 · HL · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2017 · AG
Advanced Glycation Endproducts and Cardio-Renal Disease$121,219
K24 · FY2017 · HL · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins - SUPPLEMENT$4,925
R01 · FY2017 · AG
Evaluation of HIV-associated Cardiac Dysfunction in Women$848,351
R01 · FY2016 · HL · contact PI
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2016 · AG
Determinants and Cardiovascular Consequences of Diabetes in Older Adults$1,294,893
R01 · FY2012 · HL
Determinants and Cardiovascular Consequences of Diabetes in Older Adults$1,397,528
R01 · FY2011 · HL
Determinants and Cardiovascular Consequences of Diabetes in Older Adults$1,440,971
R01 · FY2010 · HL
Determinants and Cardiovascular Consequences of Diabetes in Older Adults$1,720,863
R01 · FY2009 · HL
THROMBOPHILIA IN CRYPTOGENIC STROKE (THICK) STUDY$13,631
M01 · FY2007 · RR · contact PI
CD39 AND PLATELET REACTIVITY IN ARTERIAL AND VENOUS THROMBOSIS$152
M01 · FY2007 · RR · contact PI
Thrombophilia In Cryptogenic Stroke (THICK) Study$130,680
K23 · FY2006 · HL · contact PI
THROMBOPHILIA IN CRYPTOGENIC STROKE (THICK) STUDY$78,593
M01 · FY2006 · RR · contact PI
Thrombophilia In Cryptogenic Stroke (THICK) Study$130,680
K23 · FY2005 · HL
THROMBOPHILIA IN CRYPTOGENIC STROKE (THICK) STUDY$45,914
M01 · FY2005 · RR
Thrombophilia In Cryptogenic Stroke (THICK) Study$130,680
K23 · FY2004 · HL
THrombophilia In Cryptogenic stroKe (THICK) study$24,779
M01 · FY2004 · RR
Thrombophilia In Cryptogenic Stroke (THICK) Study$130,680
K23 · FY2003 · HL
Thrombophilia In Cryptogenic Stroke (THICK) Study$130,360
K23 · FY2002 · HL